论文部分内容阅读
目的探讨XELOX(奥沙利铂+卡培他滨)方案联合参麦注射液治疗老年晚期胃癌的临床疗效。方法将65例老年晚期胃癌患者随机分成治疗组和对照组,治疗组33例,给予XELOX方案联合参麦注射液治疗,对照组32例,仅给予XELOX方案化疗,观察两组免疫功能变化、近期疗效及毒副反应。结果治疗组的CR、PR和RR分别为6.1%、51.5%和57.6%,均高于对照组,但P>0.05。治疗组治疗结束后CD3+、CD4+、CD16+CD56+的比例和CD4+/CD8+比值显著上升,CD8+效应细胞比例下降,治疗前后有明显差异(P<0.05)。而对照组治疗前后无明显变化(P>0.05)。治疗组骨髓抑制、胃肠道反应及手足综合症的发生率均低于对照组,有显著差异(P<0.05)。结论参麦注射液联合XELOX方案治疗晚期胃癌能提高疗效,改善机体免疫功能,减轻毒副反应。
Objective To investigate the clinical efficacy of XELOX (oxaliplatin + capecitabine) combined with Shenmai injection in the treatment of elderly patients with advanced gastric cancer. Methods Sixty-five elderly patients with advanced gastric cancer were randomly divided into treatment group and control group. The treatment group was given XELOX combined with Shenmai injection. The control group was given XELOX chemotherapy only. The changes of immune function in both groups were observed. Efficacy and side effects. Results The CR, PR and RR in the treatment group were 6.1%, 51.5% and 57.6%, respectively, which were higher than those in the control group, but P> 0.05. After treatment, the ratio of CD3 +, CD4 +, CD16 + CD56 + and the ratio of CD4 + / CD8 + in treatment group increased significantly, and the proportion of CD8 + effector cells decreased. There was significant difference before and after treatment (P <0.05). The control group before and after treatment no significant change (P> 0.05). The incidence of myelosuppression, gastrointestinal reaction and hand-foot syndrome were lower in the treatment group than in the control group (P <0.05). Conclusion Shenmai injection combined with XELOX regimen in the treatment of advanced gastric cancer can improve the curative effect, improve the immune function and reduce the side effects.